Drug
Triapine clinical trials
Also written OCX-191, 3-AP and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone.
- studies test it
- 33
- open now
- 1
- in phase 3
- 1
- first study started
- 1998
Keep track of what changes. Save the triapine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
33 studies that test it; most in 2004 (11)
| Year | Studies |
|---|---|
| 1998 | 1 |
| 2000 | 2 |
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 4 |
| 2004 | 11 |
| 2005 | 1 |
| 2006 | 5 |
| 2009 | 1 |
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 16
- Phase 2
- 15
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 25
National Cancer Institute (NCI) (21) · Vion Pharmaceuticals (8) · NCIC Clinical Trials Group (1) · University Health Network, Toronto (1) · Cancer Therapeutics Research Group (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
Often tested with
Tested in the same studies.
Gemcitabine (8) · Cisplatin (6) · Fludarabine phosphate (2) · Fludarabine (2) · Cytarabine (2) · Lutetium Lu 177 dotatate (1) · Paclitaxel (1) · Doxorubicin (1)
Studies
Open first, then newest update. How each study uses triapine is read from its arms, and is right about nine times in ten.
Testing it · 33
- Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or AstrocytomaRecruitingPhase 1National Cancer Institute (NCI)NCT06860594Written as Triapine
- Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal CancersActive, not recruitingPhase 3National Cancer Institute (NCI)NCT02466971Written as Triapine
- Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine TumorsActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04234568Written as Triapine
- Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine TumorsActive, not recruitingPhase 2National Cancer Institute (NCI)NCT05724108Written as Triapine
- Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT02595879Written as Triapine
- Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of HysterectomyActive, not recruitingEarly Phase 1National Cancer Institute (NCI)NCT04494113Written as Triapine
- 3-AP in Treating Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell CarcinomaCompletedPhase 2NCIC Clinical Trials GroupNCT00075660Written as triapine
- 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic CancerCompletedPhase 2University Health Network, TorontoNCT00078975Written as triapine
- Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal CancerCompletedPhase 2National Cancer Institute (NCI)NCT00941070Written as triapine
- 3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By SurgeryCompletedPhase 1National Cancer Institute (NCI)NCT00288093Written as Triapine
- Triapine and Gemcitabine Hydrochloride in Gallbladder CancerCompletedPhase 2National Cancer Institute (NCI)NCT00075504Written as triapine
- 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous LeukemiaCompletedPhase 2National Cancer Institute (NCI)NCT00381550Written as triapine
- 3-AP in Treating Patients With Advanced or Metastatic Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT00390052Written as triapine
- 3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung CancerCompletedPhase 2Vion PharmaceuticalsNCT00064064Written as triapine
- 3-AP in Treating Patients With Advanced Prostate CancerCompletedPhase 2Vion PharmaceuticalsNCT00054015Written as triapine
- Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the PancreasCompletedPhase 2National Cancer Institute (NCI)NCT00085371Written as triapine
- 3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal JunctionCompletedPhase 2National Cancer Institute (NCI)NCT00077545Written as triapine
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or LymphomaCompletedPhase 1National Cancer Institute (NCI)NCT00293345Written as triapine
- 3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic CancerCompletedPhase 2Vion PharmaceuticalsNCT00064051Written as triapine
- 3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic CancerCompletedPhase 1Vion PharmaceuticalsNCT00016874Written as triapine
See all 33 studies that test triapine →
Given in every arm · 1 — triapine is usual care beside what is tested
Codes
What other systems call triapine · ClinicalTrials.gg INT003682
- UNII (FDA) U4XIL4091COCX-0191Confirmed FDA, Wikidata
- Wikidata Q4634115triapineConfirmed FDA, Wikidata
- NCI Thesaurus C2242TriapineOne source FDA
- DrugBank DB11940One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | U4XIL4091C | OCX-0191 | Confirmed FDA, Wikidata |
| Wikidata | Q4634115 | triapine | Confirmed FDA, Wikidata |
| NCI Thesaurus | C2242 | Triapine | One source FDA |
| DrugBank | DB11940 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.